{
    "nctId": "NCT05638594",
    "briefTitle": "Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer",
    "officialTitle": "A Randomized Controlled, Open-label, Multicenter Clinical Study of Pyrotinib Maleate Combined With Trastuzumab,Dalpiciclib, and Letrozole Versus Trastuzumab Combined With Pertuzumab, Docetaxel, and Carboplatin as Neoadjuvant Therapy for Stage II-III HR +/HER2 + Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 236,
    "primaryOutcomeMeasure": "Pathologic Complete Response Rate (tpCR: ypT0-is/ypN0)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged 18 -75 ;\n2. Willing to receive LHRH agonist therapy (premenopausal patients only);\n3. All patients were histopathologically confirmed to be estrogen receptor (ER) -positive and HER2-positive.\n4. Treatment-na\u00efve stage II-III patients with tumor stage meeting AJCC version 8 criteria;\n5. ECOG score 0-1;\n6. Organ function level must meet the following requirements:\n\n(1) bone marrow function \u2022 ANC \u2265 1.5 x 109/L ; \u2022 PLT \u2265 100 \u00d7 109/L \u2022 Hb \u2265 90 g/L ; (2) hepatic and renal function \u2022 TBIL \u2264 1.5 \u00d7 ULN; \u2022 AL and AST \u2264 3 \u00d7 ULN (ALT and AST \u2264 5 \u00d7 ULN in patients with liver metastases); \u2022 BUN and Cr \u2264 1.5 \u00d7 ULN and creatinine clearance \u2265 50 mL/min; (Cockcroft-Gault formula) (3) Echocardiography: LVEF \u2265 50%; (4) 12-lead ECG: QT interval \u2264 480 ms; 7. Able to undergo needle biopsy; 8. Voluntarily join this study to sign informed consent, have good compliance and willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);\n2. Received any other anti-tumor therapy at the same time;\n3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer;\n4. Stage IV breast cancer;\n5. Breast cancer without histopathological diagnosis;\n6. Other malignant tumors in the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;\n7. Severe heart, liver and kidney and other vital organ dysfunction;\n8. Inability to swallow, chronic diarrhea and intestinal obstruction, there are a variety of factors affecting drug administration and absorption;\n9. Participated in other drug clinical trials within 4 weeks before enrollment;\n10. Known history of hypersensitivity to the drug components of this protocol; history of immunodeficiency, including positive HIV test, HCV, active viral hepatitis B or other acquired, congenital immunodeficiency diseases, or history of organ transplantation;\n11. Had any cardiac disease, including: (1) cardiac arrhythmia requiring medication or clinically significant; (2) myocardial infarction; (3) heart failure; (4) any other cardiac disease judged by the investigator to be inappropriate for participation in this trial;\n12. Female patients who are pregnant or lactating, female patients of childbearing potential with a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial;\n13. According to the investigator 's judgment, there are concomitant diseases that seriously jeopardize the patient' s safety or affect the patient 's completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, etc.);\n14. Had a documented history of neurological or psychiatric disorders, including epilepsy or dementia.Any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}